Assessment of Pharmacodynamic Effects Following Oral Administration of Crushed Morphine Sulfate and Naltrexone Hydrochloride Extended-Release Capsules Compared with Crushed Morphine Sulfate Controlled-Release Tablets and Placebo in Nondependent Recreational Opioid Users

被引:21
作者
Setnik, Beatrice [1 ]
Sommerville, Kenneth [1 ,2 ]
Goli, Veeraindar [1 ,2 ]
Han, Ling [3 ]
Webster, Lynn [4 ]
机构
[1] Pfizer Inc, Cary, NC 27513 USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Synteract, Carlsbad, CA USA
[4] CRI Lifetree, Salt Lake City, UT USA
关键词
Abuse Potential; Pharmacodynamic Effects; Opioid; Opioid Antagonist; Morphine; Naltrexone; Controlled-Release; INTRAVENOUS MORPHINE; ABUSE LIABILITY; UNITED-STATES; DOUBLE-BLIND; FORMULATIONS; MISUSE; PAIN;
D O I
10.1111/pme.12148
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objectives. To compare the pharmacodynamic effects, including self-reports of "drug liking" and "high," of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules (MSN), crushed morphine sulfate controlled-release (CR) tablets, and placebo in an abuse potential study. Design. Randomized, double-blind, placebocontrolled, three-way crossover study. Setting. Single-center. Subjects. Nondependent recreational opioid users. Interventions. Orally administered crushed MSN (120-mg morphine sulfate and 4.8-mg naltrexone hydrochloride), crushed 120-mg morphine sulfate CR, and placebo. Outcome Measures. Subjective ratings (100-point visual analog scales) of positive drug effects (drug liking, high, good effects, take drug again, and overall drug liking), any effects, and negative effects (bad effects, feel sick, nausea, sleepy, and dizzy), along with pupillometry, pharmacokinetic (PK), and safety assessments. Results. Crushed morphine sulfate CR significantly increased ratings of all positive subjective measures relative to placebo (P < 0.0001). Crushed MSN significantly decreased all positive subjective ratings compared with morphine sulfate CR (P <= 0.005), but significantly increased ratings compared with placebo (P < 0.03). Peak pupil diameter was significantly larger for MSN than morphine sulfate (P < 0.0001). PK analysis of morphine plasma concentrations indicated that C-max was significantly lower and t(max) significantly longer for crushed MSN compared with crushed morphine sulfate CR. Plasma concentrations of naltrexone and 6-beta-naltrexol were present following crushed MSN. Conclusions. This study demonstrated that when crushed and administered orally to nondependent recreational opioid users, MSN was associated with significantly lower scores on all positive subjective measures including drug liking and high, and significantly less pupil constriction compared with crushed morphine sulfate CR.
引用
收藏
页码:1173 / 1186
页数:14
相关论文
共 29 条
[1]  
[Anonymous], 2007, CLIN ASS AB LIAB DRU
[2]  
[Anonymous], 2011, Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, P11
[3]   Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United States [J].
Birnbaum, Howard G. ;
White, Alan G. ;
Schiller, Matt ;
Waldman, Tracy ;
Cleveland, Jody M. ;
Roland, Carl L. .
PAIN MEDICINE, 2011, 12 (04) :657-667
[4]   Abuse risks and routes of administration of different prescription opioid compounds and formulations [J].
Butler, Stephen F. ;
Black, Ryan A. ;
Cassidy, Theresa A. ;
Dailey, Taryn M. ;
Budman, Simon H. .
HARM REDUCTION JOURNAL, 2011, 8
[5]   Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain [J].
Chou, Roger ;
Fanciullo, Gilbert J. ;
Fine, Perry G. ;
Adler, Jeremy A. ;
Ballantyne, Jane C. ;
Davies, Pamela ;
Donovan, Marilee I. ;
Fishbain, David A. ;
Foley, Kathy M. ;
Fudin, Jeffrey ;
Gilson, Aaron M. ;
Kelter, Alexander ;
Mauskop, Alexander ;
O'Connor, Patrick G. ;
Passik, Steven D. ;
Pasternak, Gavril W. ;
Portenoy, Russell K. ;
Rich, Ben A. ;
Roberts, Richard G. ;
Todd, Knox H. ;
Miaskowski, Christine .
JOURNAL OF PAIN, 2009, 10 (02) :113-130
[6]   Determining the clinically important difference in visual analog scale scores in abuse liability studies evaluating novel opioid formulations [J].
Eaton, Thomas A. ;
Comer, Sandra D. ;
Revicki, Dennis A. ;
Trudeau, Jeremiah J. ;
van Inwegen, Richard G. ;
Stauffer, Joseph W. ;
Katz, Nathaniel P. .
QUALITY OF LIFE RESEARCH, 2012, 21 (06) :975-981
[7]   Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxide [J].
Goli, Veeraindar ;
Webster, Lynn R. ;
Lamson, Michael J. ;
Cleveland, Jody M. ;
Sommerville, Kenneth W. ;
Carter, Eric .
HARM REDUCTION JOURNAL, 2012, 9
[8]  
Governale L., 2010, Outpatient Prescription Opioid Utilization in the U.S.
[9]   Principles of initial experimental drug abuse liability assessment in humans [J].
Griffiths, RR ;
Bigelow, GE ;
Ator, NA .
DRUG AND ALCOHOL DEPENDENCE, 2003, 70 (03) :S41-S54
[10]  
Haddox JD, 1997, CLIN J PAIN, V13, P6